Rosacea PBMC
Rosacea PBMC from clinically diagnosed donors, cryopreserved in CryoStor® CS10 within 24 hours of collection. Rosacea combines neurovascular dysregulation with innate immune activation — cathelicidin/LL-37 processing, TRP channel signalling and Demodex density. Suitable for innate immune cell characterisation, TLR stimulation assays and subtype-stratified comparative studies.
Rosacea PBMC for Innate Immune and Inflammatory Dermatology Research
Rosacea PBMC are isolated from the peripheral blood of IRB-consented donors with a clinically confirmed diagnosis of rosacea, cryopreserved in CryoStor® CS10 and processed within 24 hours of collection. These peripheral blood mononuclear cells provide a viable immune cell population for characterising the innate immune component of rosacea, alongside subtype-annotated donor metadata.
Neurovascular and Innate Immune Mechanisms in Rosacea
Rosacea is a chronic inflammatory facial dermatosis best understood as a combination of neurovascular dysregulation and innate immune activation. It is not an autoimmune disease and has no associated autoantibody; the mechanisms below are the ones with genuine support in the literature.
- Cathelicidin peptide processing is central: elevated kallikrein-5 activity generates abnormal LL-37 fragments in rosacea skin, and these fragments are proinflammatory and vasoactive.
- Transient receptor potential channels, including TRPV1 and TRPA1, mediate the neurogenic flushing, burning and stinging responses to heat, alcohol, spicy food and other recognised triggers.
- Innate immune receptors such as TLR2 are upregulated in rosacea skin and link environmental and microbial stimuli to the cathelicidin pathway.
- Increased Demodex folliculorum density is a consistent finding, particularly in papulopustular disease, and is thought to act as an innate immune stimulus rather than a classical infection.
- Mast cells are abundant in rosacea skin and sit at the interface between neuropeptide signalling and vascular and inflammatory change.
- Rosacea is fundamentally a localised cutaneous disorder, so PBMC are appropriate for characterising the circulating innate immune compartment and its reactivity to defined stimuli — not as a substitute for lesional skin. Used with that scope in mind, they support monocyte and dendritic cell phenotyping, TLR ligand stimulation and cytokine response assays.
Donor Stratification Available
- Subtype/phenotype: erythematotelangiectatic, papulopustular, phymatous, or ocular rosacea
- Severity grading where documented
- Predominant clinical features: persistent erythema, flushing, telangiectasia, papules and pustules
- Treatment status: topical metronidazole, azelaic acid, ivermectin, brimonidine, oral tetracycline-class antibiotic, isotretinoin, or treatment-naive
- Trigger sensitivity profile and disease duration where documented
- Ocular involvement and comorbid dermatological conditions where documented
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed rosacea donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- Viability and recovery reported per lot
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified rosacea diagnosis and subtype where documented
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Current and prior rosacea treatment history
- Self-reported allergies and infectious disease history
- Additional rosacea-specific data available upon request
Applications
- Innate immune cell characterisation and immunophenotyping in rosacea donors
- Monocyte and dendritic cell phenotyping and activation state analysis
- TLR ligand ex vivo stimulation and cytokine response assays
- Cathelicidin and kallikrein pathway studies in circulating immune cells
- Transcriptomic and single-cell profiling of the peripheral immune compartment
- Subtype-stratified comparative immune studies
- Target validation and screening for anti-inflammatory dermatology candidates
- Case-control study design with matched healthy donor material
Other Rosacea Specimen Types
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant donor data protection
- Documentation support available for regulatory review
Ordering & Customization
Rosacea PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full PBMC inventory, visit our human PBMC page.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.